Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retigabine and riluzole crossover study of motor nerve excitability in ALS
NL-OMON43747Phase 2Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of retigabine and riluzole in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Centre for Human Drug Research. Primary endpoint: Test-retest reliability of nerve excitability threshold tracking. Started Oct 2015; status: active, not recruiting.
02
Drugs
retigabineriluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON43747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43747.